Wyeth’s fen/phen settlement Redux
Executive Summary
The firm announces May 24 that the so-called "Seventh Amendment" of the Redux settlement receives final judicial approval. The Seventh Amendment sets aside $1.275 bil. to fund less serious cases (1"The Pink Sheet" Feb. 7, 2005, In Brief). Wyeth has reserved $21 bil. for fen/phen claims and litigation, and has paid out an estimated $15.75 bil...
You may also be interested in...
Wyeth diet drug litigation
Wyeth increases Redux litigation reserve by $4.5 bil. ($2.6 bil. net of tax), bringing total fen/phen-related charges to $21.1 bil. Wyeth has paid $13.9 bil. in claims, leaving a balance of $7.2 bil. in reserve, as of Dec. 31. The charge assumes the so-called "Seventh Amendment" settlement will be accepted, although it still awaits final court approval. The Seventh Amendment would set aside $1.275 bil. to fund less serious cases (1"The Pink Sheet" Aug. 16, 2004, In Brief)...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.